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Background : Plasmid-mediated AmpC β-lactamases (PABLs) have been detected in the strains
of Escherichia coli, Klebsiella spp., Proteus mirabilis, and Salmonella spp. PABLs may be difficult
to detect and might interfere in the therapeutic and infection-control processes. Although several
PABL-detection methods based on phenotypes have been reported, the Clinical and Laboratory
Standards Institute currently does not recommend a routine detection method for PABLs. The aim
of this study is to compare the performances of 3 phenotypic PABL detection methods.
Methods : Total 276 non-duplicated clinical isolates of E. coli (N=97), K. pneumoniae (N=136),
and P. mirabilis (N=43) were collected from 14 hospitals in Korea between April and June 2007 in
a non-consecutive and non-random manner. Multiplex PCR was performed to detect the PABL genes.
Further, 3 phenotypic detection methods-cephamycin-Hodge test, Tris-EDTA (TE) disk test, and com-
bination-disk test with 3-aminophenylboronic acid (BA)-were performed using cefoxitin and cefote-
tan disks. 
Results : PABL genes were detected by multiplex PCR in 122/276 isolates, including 14/97 E. coli,
105/136 K. pneumoniae, and 3/43 P. mirabilis isolates. The combination-disk test with BA showed higher
sensitivity (98.4%), specificity (92.2%), and efficiency (96.3%) than the cephamycin-Hodge (76.2%,
96.1%, and 88.6%, respectively) and the TE-disk (80.3%, 91.6%, and 87.9%, respectively) tests.
Conclusions : The combination-disk test with BA is a simple, efficient, and interpretable test that
can be applicable in clinical laboratories in-
volved in the detection of PABLs in clinical
isolates of E. coli, K. pneumoniae, and P. mira-
bilis. (Korean J Lab Med 2009;29:448-54)
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INTRODUCTION
AmpC β-lactamases hydrolyze extended-spectrum cepha-
losporins and are present in many gram-negative bacilli.
ampC genes are originally chromosomal in Citrobacter spp.,
Enterobacter spp., Morganella spp., Hafnia spp., and Ser-
ratia spp. [1]. Since 1989, plasmid-mediated AmpC β-lac-
tamases (PABLs) have been detected worldwide in the strains
of Escherichia coli, Klebsiella spp., Proteus mirabilis, and
Salmonella spp. [1, 2] Decreased susceptibility to cefoxitin
in Enterobacteriaceae may indicate the involvement of AmpC,
but cefoxitin resistance may also be attributable to the dec-
rease in the outer membrane permeability [3]. PABL-pro-
ducing strains may also be susceptible to cefoxitin and cefo-
tetan according to the current breakpoint criteria [4]. It may
be difficult to detect PABLs, which are known to interfere
with the therapeutic and infection control processes [5].
Therefore, it is important to develop methods that can easily
and appropriately detect PABLs in clinical isolates. Although
several phenotypic methods for their detection have been
reported, CLSI currently does not recommend testing for
PABLs [6]. Phenotypic-detection methods can be divided
into following 2 categories: ones that detect AmpC activi-
ties in enzyme extracts and the others that evaluate the
inhibitory effects induced by AmpC inhibitors. Three-dimen-
sional extraction test has been reported as a reliable en-
zyme-extraction method, but this method is complicated
and not applicable to clinical microbiology laboratories [7].
Cephamycin-Hodge test and Tris-EDTA (TE)-disk test were
reported as simple and sensitive phenotypic-detection me-
thods [5, 8]. Boronic acid (BA), cloxacillin, and Syn2190 have
been identified as AmpC inhibitors [7, 9, 10]. Several phe-
notypic-detection methods have been developed using these
inhibitors, but the one developed using BA, which was first
introduced by Yagi et al. [11], is relatively available. The aim
of this study is to compare the performance of the follow-
ing 3 phenotypic-detection methods: cephamycin-Hodge
test, TE-disk test, and combination-disk test with BA, for
identifying PABL-producing E. coli, K. pneumoniae, and
P. mirabilis strains.
MATERIALS AND METHODS
1. Strains and antibiotic susceptibility test 
A total of 276 non-duplicated clinical isolates of E. coli
(N=97), K. pneumoniae (N=136), and P. mirabilis (N=43) were
collected from 14 hospitals in Korea between April and June
2007 in a non-consecutive and non-random manner. Disk-
diffusion-susceptibility tests for cefoxitin, cefotetan, and
cefepime were performed according to the CLSI recommen-
dations [12]. 
2. Multiplex PCR for plasmid-mediated ampC genes
All the isolates were tested for plasmid-mediated ampC
genes using multiplex PCR developed by Perez-Perez and
Hanson [13]. 
3. Cephamycin-Hodge test
The surfaces of MacConkey agar (MCA) plates were inocu-
latedwith a lawn of the indicator strain, E. coli ATCC 25922,
according to the CLSI disk-diffusion method [12]. After the
agar surface dried, a test strain was heavily streaked from
the center of the plate to the periphery and a cephamycin
disk (BD Diagnostic Systems, Sparks, MD, USA) was placed
at the center. The plates were incubated overnight at 35℃,
and the presence of definite growth of the indicator organ-
ism in the inhibition zone along with the test strain was
interpreted as positive.
4. TE-disk test
TE disks were prepared in-house by applying 20 μL of a
1:1 mixture of saline and 100× Tris-EDTA (Sigma-Aldrich
Corp., St. Louis, MO, USA) to sterile filter paper disks, fol-
lowing which the disks were dried and stored at 2-8℃. A
lawn of E. coli ATCC 25922 was inoculated on the surface
of a Mueller-Hinton agar (MHA) plate. Immediately prior
to incubation, a TE disk premoistened with 20 μL of saline
was inoculated with several colonies of the test organism
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and placed face down on the MHA plate adjacent to a disk
containing any one of the following: cephamycins, cefoxitin,
or cefotetan. The plates were incubated overnight, and an
indentation in the zone of inhibition was interpreted as posi-
tive [5].
5. Combination-disk test with boronic acid
3-Aminophenylboronic acid (120 mg; Sigma-Aldrich Corp.,
St. Louis, MO, USA) was dissolved in 3 mL of dimethyl sul-
foxide and 3 mL of sterile distilled water was added to this
solution [4]. Next, 20 μL of the BA solution was dispensed
onto disks containing cefoxitin or cefotetan. A test strain
was inoculated on MHA plates according to the CLSI guide-
line [12]. Disks containing cefoxitin, cefotetan, cefoxitin plus
400 μg of BA, and cefotetan plus 400 μg of BA were plated
on the MHA plates. The plates were incubated overnight,
and an increase in the zone size of ≥5 mm for either cefox-
itin or cefotetan in the presence of BA compared with that
of either drug alone was considered as positive result [4, 11].
6. Data analysis
Sensitivity was defined as the probability that a positive
test result (TP) indicates the presence of PABL on the basis
of the plasmid-mediated ampC gene-producing strains
(PCR+), i.e., TP/PCR+. Specificity was defined as the prob-
ability that a negative test result (TN) excludes the presence
of PABL from the plasmid-mediated ampC gene non-pro-
ducing strains (PCR-), i.e., TN/PCR-. Efficiency (accuracy)
was defined as the ratio of the true findings (true-positive+
true-negative results) to all the test results. For compar-
ing the efficacy of the phenotypic-detection methods, we
used the Cochran Q test, and a P value <0.05 was consid-
ered statistically significant. Statistical analyses were per-
formed using Microsoft Excel 2000 (Microsoft Corporation,
Redmond, WA, USA). 
RESULTS
All the AmpC PCR-positive strains were non-suscepti-
ble to cefoxitin, while 14 strains (9 K. pneumoniae, 4 E. coli,
and 1 P. mirabilis) were susceptible to cefotetan (Table 1).
Of the 276 strains tested, 122 were positive with the mul-
tiplex PCR (E. coli, 14/97; K. pneumoniae, 105/136; and P.
mirabilis, 3/43). DHA group genes were predominantly ob-
served in E. coli (N=8) and K. pneumoniae (N=102) and were
also observed in 1 of the 3 PABL-producing P. mirabilis.
MOX group genes were detected in all the studied species,
but the prevalence was relatively low in E. coli (N=2) and
K. pneumoniae (N=1). Of the 3 PABL-producing P. mirabilis,
2 were MOX-type enzyme producers. CIT group genes (CMY-
like genes originated from Citrobacter freundii) were detect-
ed in only 3 strains of E. coli [13]. Amplicons of EBC group
Abbreviations: S, susceptible; I, intermediate; R, resistant.
Species AmpC PCR
N of isolates
Cefoxitin
S I R
Cefotetan
S I R
Cefepime
S I R
E. coli + 14 4 2 8 13 1
- 51 11 21 72 7 4 73 4 6
K. pneumoniae + 1 104 9 15 81 100 2 3
- 15 6 10 27 2 2 26 4 1
P. mirabilis + 1 2 1 1 1 3
- 37 1 2 39 1 40
All + 0 2 120 14 18 90 116 3 3
- 103 18 33 138 9 7 139 8 7
Sensitivity (%) 100.0 88.5 -
Specificity (%) 66.9 89.6 -
Table 1. Disk diffusion results of cefoxitin, cefotetan, and cefepime compared with results of AmpC PCR
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genes (including MIR-1 and ACT-1, which were originated
from Enterobacter cloacae) were observed in 1 E. coli and
2 K. pneumoniae strains [13] (Table 2). 
A total of 93 PABL-producing strains were positive with
the cephamycin-Hodge test, but 29 PABL-producing strains
were not detected by this method. The overall sensitivity,
specificity, and efficiency of the cephamycin-Hodge test were
76.2%, 96.1%, and 88.6%, respectively. By TE -disk test, 98
strains were determined as PABL-producers, while 24 strains
were false-negatives. The overall sensitivity, specificity,
and efficiency of the TE-disk test were 80.3%, 91.6%, and
87.9%, respectively. Combination-disk test with BA detect-
ed 120 strains of the 122 PABL-producers, but 12 PABL-
non-producers were also tested positive by this method. The
overall sensitivity, specificity, and efficiency of the combi-
nation-disk test with BA were 98.4%, 92.2%, and 96.3%,
respectively (Table 3). The efficiency of the combination-
disk test with BA was significantly better than that of the
former 2 methods (Cochran Q=16.1, P<0.05).
The performance of the phenotypic-detection methods
was also analyzed on the basis of the tested antibiotic disks,
i.e., cefoxitin or cefotetan. The sensitivity of cefoxitin-Hodge
test was 74.6%, while that of cefotetan-Hodge was 14.8%.
A similar result was obtained by TE-disk test when it was
evaluated with a single disk of cefoxitin or cefotetan. The
most sensitive results were obtained with the combination
disk test with BA: the sensitivity was 86.9% with cefoxitin
and 89.3% with cefotetan (Table 4). 
DISCUSSION
There is no CLSI guidelines for phenotypic methods to
screen and detect AmpC activity in clinical isolates of E. coli,
Species
Types of ampC genes
CIT DHA EBC MOX Total
E. coli 3 8 1 2 14
K. pneumoniae 0 102 2 1 105
P. mirabilis 0 1 0 2 3
Table 2. Distribution of plasmid mediated ampC genes within
study isolates 
Species AmpC PCR
Cefoxitin
Positive (%) Negative (%)
Hodge
Positive (%) Negative (%)
TE-disk
Positive (%) Negative (%)
E. coli Positive 13 (92.9) 1 (7.1) 5 (35.7) 9 (64.3) 9 (64.3) 5 (35.7)
Negative 10 (12.0) 73 (88.0) 1 (1.2) 82 (98.8) 3 (3.6) 80 (96.4)
K. pneumoniae Positive 104 (99.0) 1 (1.0) 86 (81.9) 19 (18.1) 88 (83.8) 17 (16.2)
Negative 2 (6.5) 29 (93.5) 2 (6.5) 29 (93.5) 7 (22.6) 2 (77.4)
P. mirabilis Positive 3 (100) 0 (0.0) 2 (66.7) 1 (33.3) 1 (33.3) 2 (66.7)
Negative 0 (0.0) 40 (100) 3 (7.5) 37 (92.5) 3 (7.5) 37 (92.5)
All Positive 120 (98.4) 2 (1.6) 93 (76.2) 29 (23.8) 98 (80.3) 24 (19.7)
Negative 12 (7.8) 142 (92.2) 6 (3.9) 148 (96.1) 13 (8.4) 141 (91.6)
Efficiency 96.3% 88.6% 87.9%
Table 3. Comparison of 3 phenotypic detection methods for plasmid-mediated AmpC β-lactamase producing-isolates
Species
Boronic acid
Cefoxitin Cefotetan
Hodge
Cefoxitin Cefotetan
TE-disk
Cefoxitin Cefotetan
E. coli Sensitivity 78.6 71.4 28.6 21.4 64.3 21.4
Specificity 88.0 92.8 98.8 98.8 96.4 100.0
K. pneumoniae Sensitivity 87.6 92.4 81.0 13.3 83.8 1.9
Specificity 93.5 100.0 93.5 100.0 77.4 100.0
P. mirabilis Sensitivity 100.0 66.7 66.7 33.3 33.3 33.3
Specificity 97.5 100.0 92.5 100.0 92.5 100.0
All Sensitivity 86.9 89.3 74.6 14.8 80.3 4.9
Specificity 91.6 96.1 96.1 99.4 91.6 100.0
Table 4. Sensitivity and specificity of the plasmid-mediated AmpC β-lactamase detection methods depending on the antibiotics used (%)
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K. pneumoniae, and P. mirabilis [6]; these strains could be
non-susceptible to cephamycin mainly because of PABLs.
Although several phenotypic screening methods have been
used in clinical microbiology laboratories for the detection
of PABLs in clinical isolates, only a few studies have thus
far evaluated the performance of various phenotypic screen-
ing methods [14, 15]. Therefore, we attempted to compare
the performance of the commonly used phenotypic screen-
ing methods.
Our data showed that all plasmid-mediated ampC gene
producers were non-susceptible to cefoxitin, while some
were susceptible to cefotetan. Therefore, cefoxitin was con-
sidered as a better PABL-screening indicator than cefote-
tan. This could be because of the fact that cefotetan is more
active than cefoxitin [16]. 
In this study, 4 groups of ampCgenes, namely, CIT, DHA,
EBC, or MOX, were analyzed, and ACC- and FOX-type
AmpC producers were not included in the analysis. There-
fore, the performance for ACC and FOX enzyme-produc-
ing strains might be different from that of the strains ana-
lyzed in this study.
We have reported that more sensitive results can be ob-
tained if modified-Hodge tests are conducted on MCA plates
(reported in the 18th ECCMID, 2008, P-892). Lee et al. re-
ported in the 18th ECCMID, showed that bile improved the
performance of modified-Hodge test when MCA was used
(2008, P-891). Although we used carbapenemase-produc-
ing strains in this study, it was apparent that better results
could have been obtained by performing cephamycin-Hodge
test using MCA. Therefore, we used MCA instead of MHA
to detect AmpC β-lactamase-producing strains.
The usefulness of the antimicrobial-disk-susceptibility
test using cephamycins as the phenotypic screening test
for PABL-producers was investigated. Because all PABL
producers were non-susceptible to cefoxitin, the suscepti-
bility to cefoxitin can be used to rule out the possibility of
PABL producers (Table 1). Several strains could be regard-
ed as false-positives without even conducting the pheno-
typic AmpC confirmatory test; therefore, there might be
serious risks involved in the selection of antimicrobial agents
for the treatment of infections caused by these strains. The
sensitivity of cefotetan susceptibility was higher (88.5%) than
Hodge test or TE disk test, but not higher than that of the
combination-disk test; however, the specificity was the low-
est (89.6%) compared to that of all th 3 phenotypic-detec-
tion methods (Table 1, 3). Although the possibility of obtain-
ing false-positive results was reduced by using cefotetan,
the sensitivity also decreased. The results of cefepime sus-
ceptibility seemed to be unrelated to PABL-producers (Table
1). Resistance to cefoxitin as well as to oxyimino-β-lactams
is not specific to AmpC enzyme because cefoxitin resistance
can also be produced by certain other enzymes or by dec-
reased permeability of the outer membrane [17-22]. Other
confirmatory tests are required in this regard [23].
The results of the 3 methods varied depending on the anti-
biotics and bacterial species used. Hodge test and TE-disk
test performed using cefoxitin showed better results than
those performed using cefotetan, but the combination-disk
test with BA showed relatively better results using cefotetan
instead of cefoxitin (Table 4). This could be because of the
increase in the inhibitory effects of BA by the higher activity
of cefotetan. Using cefoxitin, the sensitivity of the combi-
nation-disk test with BA was 86.9%. Tan et al. [14] reported
a 94% sensitivity of the combination-disk test with BA when
the zone size of ≥4 mm was used as a positive criterion. We
obtained a 92.6% sensitivity using the same cutoff criteri-
on, but the specificity was reduced from 91.6% to 87.0%. On
the other hand, when the test was performed with cefotetan
alone using the same criterion, the sensitivity of the com-
bination-disk test increased to 95.1% from 86.9% (data not
shown). Collectively, the best results were obtained when
each method was considered using both cefoxitin and cefote-
tan. The sensitivity of the combination-disk test with BA
was 98.4% when the results were evaluated using both cefox-
itin and cefotetan and when the increase in zone size of ≥5
mm was used as a positive criterion (Table 3). In addition,
Song et al. [15] reported that the combination of cefoxitin-
BA and cefotetan-BA disk tests detected 98.4% of PABL-
producing strains. Two PABL-producing strains-1 E. coli
and the other K. pneumoniae-showed false-negative results
when combination-disk test with BA was used, and all the
ampC gene types of these strains were of the DHA group.
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Of the 12 false-positive strains, 10 were E. coli (Table 3).
Such phenotypic results for these E. coli strains might be
because of the increased activities of chromosomal AmpCs,
but it is necessary to determine the cause of obtaining false-
positive results in the 2 K. pneumoniae strains. The sensi-
tivities of the Hodge test and TE-disk test were 76.2% and
80.3%, respectively. It was difficult and obscure to interpret
the results of the Hodge test or TE-disk test, and the test
procedures were relatively more complex than the proce-
dure of the combination-disk test. Among the 3 methods
tested, the combination-disk test was found to be the most
sensitive and efficient test (Table 3). However, recently, a
study showed that 3-aminophenylboronic acid inhibited the
activity of KPC-type β-lactamase [24]. Doi et al. [24] re-
ported that 3-aminophenylboronic acid could be used for
detecting the expression of KPC-type β-lactamase in K.
pneumoniae and E. coli. The only limitation of our study is
that it lacked KPC-type β-lactamase-producing strains. 
In conclusion, we evaluated the performance of 3 pheno-
typic-detection methods for identifying PABL-producing
E. coli, K. pneumoniae, and P. mirabilis strains. The sus-
ceptibility to cefoxitin can be used as a better screening in-
dicator than that to cefotetan. The performance of the 3
screening methods can be increased by using both cefox-
itin and cefotetan. The combination-disk test with BA is a
simple, sensitive, and interpretable test that can be appli-
cable in clinical laboratories involved in the detection of
PABL-producing E. coli, K. pneumoniae, and P. mirabilis
strains.
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